Centralized Pan-Russian Survey on the Undertreatment of Hypercholesterolemia (CEPHEUS)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01221584
First received: October 14, 2010
Last updated: February 29, 2012
Last verified: February 2012

October 14, 2010
February 29, 2012
October 2010
March 2011   (final data collection date for primary outcome measure)
Establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the All-Russian Scientific Cardiology Society guidelines/the Fourth Joint European Task Force guidelines [ Time Frame: 1 visit - 1-3 days ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01221584 on ClinicalTrials.gov Archive Site
  • Establish the proportion of patients on lipid-lowering treatment reaching the LDL-C goals according to the Russian guidelines in the following sub-populations: Primary/secondary prevention patients, Patients with metabolic syndrome [ Time Frame: 1 visit - 1-3 days ] [ Designated as safety issue: No ]
  • Establish the proportion of patients on lipid-lowering treatment reaching the LDL-C goals according to the FJETF/ NCEP ATP III guidelines, in all population and in Primary/secondary prevention patients, Patients with metabolic syndrome [ Time Frame: 1 visit - 1-3 days ] [ Designated as safety issue: No ]
  • Establish the proportion of patients on lipid-lowering treatment reaching the non HDL-C goals according to the NCEP ATP III / updated 2004 NCEP ATP III guidelines in the sub-population patients with fasting triglycerides >200 mg/dL (2.26mmol/L) [ Time Frame: 1 visit - 1-3 days ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Centralized Pan-Russian Survey on the Undertreatment of Hypercholesterolemia
Centralized Pan-Russian Survey on the Undertreatment of Hypercholesterolemia

The purpose of the study is to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the All-Russian Scientific Cardiology Society guidelines/ the 4th Joint European Task Force guidelines.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Subject on lipid lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks..

Dyslipidaemia
Not Provided
1
Subject 18 years of age or older on lipid lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks..
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1000
March 2011
March 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subject must be 18 years of age or older of either gender or race.
  • Subject must provide informed consent and comply with the survey procedures.
  • Subject is on lipid lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks.

Exclusion Criteria:

  • Subjects who are unwilling or unable to provide informed consent
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Russian Federation
 
NCT01221584
NIS-CRU-DUM-2010/1
No
AstraZeneca
AstraZeneca
Not Provided
Study Director: Alexey Stepanov, Prof AstraZeneca
Principal Investigator: Prof. Boytsov RKNPK
Principal Investigator: Acad Oganov Center of preventive medicine
AstraZeneca
February 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP